Pravibismane (inhaled)

About Microbion

Microbion is a private, clinical-stage biotech developing first-in-class therapeutics targeting biofilm-related and resistant infections. Its lead asset, pravibismane, is a broad-spectrum antimicrobial with a novel mechanism of action that halts microbial metabolism and disrupts biofilms, positioning it for serious unmet needs in diabetic foot ulcers and orthopedic infections. The company employs a site-specific delivery strategy to maximize local efficacy and safety, with two Phase 2 programs and backing from venture investors like Quark Venture.

Therapeutic Areas